Abstract:Introduction Estrogen signaling is pivotal in the progression of estrogen receptor positive breast cancer primarily by the regulation of cell survival and proliferation. Micro (mi)RNAs have been demonstrated to be regulated by estrogen to mediate estrogenic effects. Herein, we determined the role of estrogen regulated miR-26 and its underlying molecular mechanisms associated with estrogen receptor (ER)+ breast cancer proliferation. Methods The expression of miR-26a and miR-26b was evaluated by real-time quantitative (RT)-PCR. The expression of miR-26a or miR-26b was modulated in ER+ breast cancer cells (MCF-7 and T47D) and tumor cell growth in vitro and an in vivo xenograft model was determined. Bioinformatics analyses were utilized to screen for estrogen responsive genes, which were also predicted to be targeted by miR-26. Luciferase reporter assays were performed to confirm miR-26 regulation of the 3' UTR of target genes. The levels of miR-26 target genes ( CHD1 , GREB1 and KPNA2 ) were evaluated by western blotting and immunohistochemistry. Results Estrogen reduced the expression of miR-26a and miR-26b in ER+ breast cancer cells. Forced expression of miR-26a or miR-26b significantly inhibited the estrogen stimulated growth of ER+ breast cancer cells and tumor growth in xenograft models, whereas miR-26a/b depletion increased the growth of ER+ breast cancer cells in the absence of estrogen treatment. Screening of estrogen responsive genes, which were also predicted to be targeted by miR-26, identified GREB1 and nine other genes ( AGPAT5 , AMMECR1 , CHD1 , ERLIN1 , HSPA8 , KPNA2 , MREG, NARG1, and PLOD2 ). Further verification has identified nine genes ( AGPAT5, CHD1, ERLIN1, GREB1, HSPA8, KPNA2, MREG, NARG1 and PLOD2 ) which were directly targeted by miR-26 via their 3′ UTR. Functional screening suggested only three estrogen regulated miR-26 target genes ( CHD1, GREB1 and KPNA2 ) were involved in the regulation of estrogen promoted cell proliferation. Depletion of either CHD1, GREB1 or KPNA2 significantly abrogated the enhanced growth of ER+ breast cancer cells due to miR-26 depletion. We further demonstrated that estrogen stimulated c-MYC expression was both sufficient and necessary for the diminished expression of miR-26a and miR-26b. Conclusions We have identified a novel estrogen/MYC/miR-26 axis that mediates estrogen stimulated cell growth via CHD1, GREB1 and KPNA2.

Synuclein (cid:1) Stimulates Membrane-Initiated Estrogen Signaling by Chaperoning Estrogen Receptor (ER)- (cid:2) 36, a Variant of ER- (Cid:2)

Synuclein Γ Stimulates Membrane-Initiated Estrogen Signaling by Chaperoning Estrogen Receptor (Er)-Α36, a Variant of ER-α

Stimulation of Estrogen Receptor Signaling by γ Synuclein

Stimulation Of Estrogen Receptor Signaling By Gamma Synuclein

Neuronal Protein Synuclein Gamma Predicts Poor Clinical Outcome in Breast Cancer

Expression of Neuronal Protein Synuclein Gamma Gene As a Novel Marker for Breast Cancer Prognosis

Synuclein Gamma Protects HER2 and Renders Resistance to Hsp90 Disruption

Synuclein Γ Protects Akt and Mtor and Renders Tumor Resistance to Hsp90 Disruption

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells

Sirna-Mediated Suppression of Synuclein Γ Inhibits MDA-MB-231 Cell Migration and Proliferation by Downregulating the Phosphorylation of AKT and ERK

Synuclein-γ Promotes Migration of MCF7 Breast Cancer Cells by Activating Extracellular-Signal Regulated Kinase Pathway and Breaking Cell-Cell Junctions.

Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2

Ebag9 Inducing Hyporesponsiveness Of T Cells Promotes Tumor Growth And Metastasis In 4t1 Murine Mammary Carcinoma

A novel variant of estrogen receptor-alpha is expressed in ER-negative breast cancer and mediates membrane-initiated estrogen signaling

Synuclein Gamma Compromises Spindle Assembly Checkpoint And Renders Resistance To Antimicrotubule Drugs

Short Communication Stage-specific Expression of Breast Cancer-specific Gene -Synuclein 1

Synuclein gamma compromise spindle assembly checkpoint and renders resistance to antimicrotubule drug

Stage-specific expression of breast cancer-specific gene gamma-synuclein.

Unconventional secretion of synuclein-γ promotes tumor cell invasion.

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer